Asia’s biotech moment: From regional strength to global impact

AT THIS year’s JP Morgan Healthcare Conference in San Francisco – the largest annual investment gathering in the global healthcare industry – one theme stood out: Asia is no longer peripheral to global biotech but is central to it.

The region is playing an increasingly pivotal role in how new medicines are discovered, developed and brought to patients worldwide. 

What is changing is not only where innovation originates, but also how it moves across borders. Asia is building the connective tissue that enables faster clinical development, benefiting from the region’s vast and diverse patient population, greater regulatory alignment, deeper capital pools and increasingly sophisticated cross-border partnerships.